<DOC>
	<DOCNO>NCT02427620</DOCNO>
	<brief_summary>The goal clinical research study learn combination ibrutinib rituximab plus combination 2 different intensive chemotherapy regimens help control MCL . The safety drug combination also study .</brief_summary>
	<brief_title>A Study Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation Newly Diagnosed Young Patients With Mantle Cell Lymphoma</brief_title>
	<detailed_description>Study Drug Administration : This study 2 Parts . If find eligible study , begin Part 1 study . At time may give drug help prevent decrease side effect , nausea vomiting . You may ask study staff information drug give risk . Part 1 : Part 1 last 12 cycle . Each cycle 28 day . Every day take 4 ibrutinib capsule 1 cup ( 8 ounce ) water . You must take 4 capsule time every day , least 30 minute least 2 hour eat meal . Do open capsule dissolve . If miss dose , take 6 hour time would take . If later 6 hour , skip dose start take capsule time usual next day . You need fill diary card information take ibrutinib . You bring diary card appointment . On Days 1 , 8 , 15 , 22 Cycle 1 , receive rituximab vein . The first dose take 6-8 hour . After , dose take 4 hour . You receive rituximab vein 4 hour Day 1 Cycles 3-12 . You receive drug Cycle 2 . For patient , may receive rituximab dose 2 day . Your doctor tell best . You check every 2 cycle learn may respond . Based response , may start Part 2 study . Part 2 : During part 2 , depend response Part 1 , receive 2 alternate combination drug ( first combination first cycle , second combination second cycle , ) 2-8 cycle . Each cycle 28 day . First combination : You receive follow drug odd-numbered cycle ( Cycles 1 , 3 , 5 , 7 ) Part 2 : - Rituximab vein 6 hour Day 1 - Dexamethasone either mouth vein Days 1-4 - Cyclophosphamide vein ( 3 hour time ) 2 time day Days 2-4 - Mesna vein non-stop Days 2-4 - Doxorubicin vein 15-30 minute Day 5 - Vincristine vein 15-30 minute Day 5 To help prevent infection , also receive Filgrastim ( G-CSF ) injection skin , start 24-36 hour end doxorubicin infusion . You continue receive injection every day white blood cell count recover . Second combination : You receive follow drug even-numbered cycle ( Cycles 2 , 4 , 6 , 8 ) Part 2 : - Rituximab vein 6 hour Day 1 - Methotrexate vein 24 hour Day 2 - Cytarabine vein ( 2 hour time ) 2 time day Days 3-4 When receive methotrexate , also give leucovorin mouth help prevent side effect . Blood ( 1 tablespoon ) draw 24 48 hour end methotrexate infusion study doctor learn best stop give leucovorin . You receive G-CSF doxorubicin white blood cell count recover . Study Visits Part 1 : On Day 1 every cycle : - You physical neurological exam . - Blood ( 2 tablespoon ) draw routine test check status disease . - If become pregnant , blood ( 1½ tablespoon ) urine pregnancy test . - If doctor think need , bone marrow biopsy and/or aspiration check status disease . - If study doctor think need , gastrointestinal endoscopy . - If study doctor think need , PET/CT scan check status disease . On Days 8 , 15 , 22 Cycle 1 , physical exam . On Day 1 every odd-numbered cycle ( Cycles 3 , 5 , 7 , ) , study doctor think need , CT scan check status disease . If CT scan show disease gotten good , PET/CT scan end Part 1 . If doctor think need base result screen bone marrow biopsy and/or colonoscopy , test repeat end Part 1 . Study Visits Part 2 : On Day 1 every cycle : - You physical neurological exam . - You EKG . - Blood ( 2 tablespoon ) draw routine test check status disease . - If become pregnant , blood ( 1½ tablespoon ) urine pregnancy test . Up 3 time week Days 8-28 Cycles , blood ( 2 tablespoon time ) drawn routine test . At end Cycles 2 , 4 , 6 , 8 , every 3-6 cycle , CT scan chest x-ray check status disease . Length Treatment : You may continue take study drug Part 1 12 cycle . You may continue take study drug Part 2 8 cycle . You longer able take drug disease get bad , intolerable side effect occur , unable follow study direction . End-of-Treatment Visit : After finish taking study drug : - You physical neurological exam . - Blood ( 2 tablespoon ) draw routine test check status disease . - If doctor think need , PET/CT scan and/or bone marrow biopsy/aspiration check status disease . - If doctor think need , gastrointestinal endoscopy . - If become pregnant , blood ( 1½ tablespoon ) urine pregnancy test . Long Term Follow-Up : After end-of-treatment visit disease gotten bad , return clinic visit every 4 month 2 year , every 6 month 2 year , every year see . At visit : - Blood ( 2 tablespoon ) draw routine test check status disease . - You PET/CT scan check status disease . This investigational study . Ibrutinib FDA approve commercially available treatment patient MCL . Rituximab FDA approve treatment non-Hodgkin 's lymphoma certain type leukemia . Using 2 drug combination investigational . All drug Part 2 standard care treatment lymphoma . Up 100 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>1 . Patient confirm diagnosis mantle cell lymphoma Blymphocyte antigen CD20 ( CD20 ) positivity tissue biopsy . 2 . Patients MCL must symptomatic need immediate therapy . Symptoms nature MCL include follow : ) blastoid variant , b ) pleomorphic variant , c ) B symptom , ) Mantle Cell International Prognostic Score ( MIPI ) &gt; 3 , e ) Antigen KI67 ( ki67 ) &gt; 30 % , f ) bulky tumor &gt; 5 cm , g ) disease threaten organ function , h ) elevate Lactate Dehydrogenase ( LDH ) , ) peripheral blood white blood cell ( PB WBC ) &gt; 50,000 , j ) pancytopenia due bone marrow MCL , k ) patient 's choice due anxiety ; l ) pain due lymphoma . 3 . Patient newly diagnose disease prior therapy . 4 . Understand voluntarily sign IRBapproved inform consent form . 5 . Age &gt; /= 18 &lt; /= 65 year time signing informed consent . 6 . Patients bidimensional measurable disease use Cheson criterion ( Measureable disease CT scan define least 1 lesion measure =/ &gt; 1.5 cm single dimension . ) Gastrointestinal bone marrow spleen patient allowable . 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status 2 less 8 . An absolute neutrophil count ( ANC ) &gt; 1,000/mm^3 platelet count &gt; 100,000/mm^3 ( Patients bone marrow infiltration MCL eligible ANC &gt; /= 500/mm^3 [ growth factor allow ] platelet level equal &gt; 20,000/mm^3 . These patient discuss either principal investigator ( PI ) CoPI study final approval ) . 9 . Serum bilirubin &lt; 1.5 mg/dl Cr Clearance &gt; /= 30 mL/min , Aspartate transaminase ( AST ) / serum glutamic oxaloacetic transaminase ( SGOT ) Alanine transaminase ( ALT ) / serum glutamicpyruvic transaminase ( SGPT ) &lt; 2 x upper limit normal &lt; 5 x upper limit normal hepatic metastasis present . Gilbert 's disease allow . 10 . Cardiac ejection fraction &gt; /= 50 % Echocardiogram ( ECHO ) multiple gated acquisition scan ( MUGA ) . 11 . Disease free prior malignancy exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast , malignancy remission ( include prostate cancer patient remission radiation therapy , surgery brachytherapy ) , actively treat . 12 . Females childbearing potential ( FCBP ) * must negative serum urine pregnancy test ( within 30 day initiation protocol therapy ) must willing use acceptable method birth control . Men must agree use latex condom sexual contact female childbearing potential even successful vasectomy . *A female childbearing potential sexually mature woman : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) . 1 . Any serious medical condition include limited , uncontrolled hypertension , uncontrolled diabetes mellitus , active/symptomatic coronary artery disease , chronic obstructive pulmonary disease ( COPD ) , renal failure , active hemorrhage , psychiatric illness , investigator opinion place patient unacceptable risk would prevent subject signing informed consent form . 2 . Pregnant breast feeding female . 3 . Known human immunodeficiency virus ( HIV ) infection . 4 . Patients active Hepatitis B C infection ( include patient prior Hepatitis B vaccination . ) These patient clear gastrointestinal ( GI ) consultation Hepatitis B Infectious Disease consult Hepatitis C. 5 . All patient central nervous system lymphoma . 6 . Significant neuropathy ( Grades 3 4 , Grade 2 pain ) within 14 day prior enrollment . 7 . Contraindication require concomitant drug supportive treatment intolerance hydration due preexist pulmonary cardiac impairment include pleural effusion require thoracentesis ascites require paracentesis unless due lymphoma . 8 . Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel ulcerative colitis , symptomatic inflammatory bowel disease , partial complete bowel obstruction , gastrointestinal condition could interfere absorption metabolism ibrutinib . 9 . Major surgery within 4 week initiation therapy . Clearance letter primary physician require . 10 . Requires anticoagulation warfarin equivalent vitamin K antagonist . 11 . Requires treatment strong Cytochrome P4503A ( CYP3A ) inhibitors 12 . Patients New York Heart Association ( NYHA ) Class III IV heart failure , myocardial infarction precede 6 month , significant conduction abnormality , include limited 2nd degree atrioventricular block ( AV block ) type II , 3rd degree block , QT prolongation ( QTc &gt; 500 msec ) , sick sinus syndrome , ventricular tachycardia , symptomatic bradycardia ( heart rate &lt; 50 bpm ) , hypotension , light headedness syncope . Patients persistent uncontrolled atrial fibrillation exclude . The protocol exclude patient recently stent recommendation cardiologist need stay anticoagulant warfarin equivalent vitamin K antagonist . 13 . Acute infection require treatment ( IV antibiotic , antiviral , antifungal ) within 14 day prior initiation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Mantle cell lymphoma</keyword>
	<keyword>MCL</keyword>
	<keyword>B-lymphocyte antigen</keyword>
	<keyword>CD20</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>PCI-32765</keyword>
	<keyword>Imbruvica</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Mesna</keyword>
	<keyword>Mesnex</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Doxorubicin hydrochloride</keyword>
	<keyword>Adriamycin PFS</keyword>
	<keyword>Adriamycin RDF</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Rubex</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine arabinosine hydrochloride</keyword>
	<keyword>Citrovorum</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Wellcovorin</keyword>
</DOC>